Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.
Fiche publication
Date publication
juillet 2023
Journal
Clinical and translational radiation oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MARTIN Etienne
Tous les auteurs :
Levy A, Khalifa J, Martin E, Botticella A, Quevrin C, Lavaud P, Aldea M, Besse B, Planchard D, Barlesi F, Deutsch E, Massabeau C, Doyen J, Le Péchoux C
Lien Pubmed
Résumé
The role of local ablative treatments, including stereotactic body radiotherapy (SBRT), is an area of active research in oligometastatic patients. Small cell lung cancer (SCLC) has a poor prognosis, with common diffuse metastatic evolution. We evaluated the outcomes after SBRT in uncommon oligoprogressive/oligorecurrent SCLC presentation.
Mots clés
Local radical treatment, Lung cancer, Oligometastases, Stereotactic body radiotherapy (SBRT)
Référence
Clin Transl Radiat Oncol. 2023 07;41:100637